| Date issued | Product | Safety information |
| 01/11/41 |
Hemlibra (Emicizumab)
|
Hemlibra® (Emicizumab) and it’s known interaction with certain laboratory assays in patients who become infected with the novel corona virus that causes COVID-19.CLICK HERE |
| 14/09/41 |
Megamox (Amoxicillin / Clavulanic acid)
|
Megamox® 625mg tablets is associated with a typographic error in the units for the weight of the product stated on the aluminum foil.CLICK HERE |
| 08/09/41 |
XELJANZ (tofacitinib)
|
XELJANZ (tofacitinib): increased risk of venous thrombo-embolism and increased risk of serious and fatal infections.CLICK HERE |
| 17/07/41 |
Ecalta (Anidulafungin)
|
Ecalta 100mg Powder for Concentrate for Solution for Infusion (Anidulafungin): Solution for Infusion must no longer be frozen.CLICK HERE |
| 17/07/41 |
Curam (Amoxicillin / Clavulanic acid)
|
Update on instruction for the preparation of Curam® (Amoxicillin Clavulanic Acid POS - powder for Oral Suspension) bottles.CLICK HERE |
| 16/06/41 |
Hydrochlorothiazide
|
Hydrochlorothiazide - Risk of non-melanoma skin cancer (basal cell carcinoma, squamous cell carcinoma).CLICK HERE |
| 21/05/41 |
Olmepress (Olmesartan)
|
Restriction of combined use of medicines affecting the renin-angiotensin aldosterone system (RAAS) for medicinal products containing Olmepress (Olmesartan).CLICK HERE |
| 15/04/41 |
Kyprolis® ( Carfilzomib)
|
Kyprolis (carfilzomib) – New Safety Information: Risk of Progressive Multifocal Leukoencephalopathy (PML) and Hepatitis B Virus (HBV) Reactivation.CLICK HERE |
| 11/04/41 |
Esbriet® (Pirfenidone)
|
Important Safety Update on ESBRIET® (pirfenidone) and Drug-Induced Liver Injury (DILI).CLICK HERE |
| 17/03/41 |
FEGONA®
|
FEGONA (fingolimod) – New contraindication in pregnant women and in women of childbearing potential not using effective contraception . CLICK HERE |